20
Participants
Start Date
January 23, 2009
Primary Completion Date
April 30, 2011
Study Completion Date
March 31, 2014
Nilotinib
Memorial Sloan Kettering Cancer Center, New York
Moffitt Cancer Center, Tampa
University of Chicago, Chicago
University of Colorado, Aurora
The Angeles Clinic and Research Institute, Santa Monica
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
Brigham and Women's Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Massachusetts General Hospital
OTHER
Novartis
INDUSTRY
Dana-Farber Cancer Institute
OTHER